Hormonal Migraine Prevention: What Works

Written and medically reviewed by Tae Ho Guak, MD, board-certified neurologist · Reviewed July 2026 · Editorial policy

Summary

Menstrual migraine is a headache disorder occurring between 2 days before and 3 days after menstrual onset, with a sharp decline in estrogen serving as the key trigger. Compared to general migraine, it presents with greater pain intensity, longer duration, and tends to show poor response to triptan monotherapy, making a separate “mini-prophylaxis” strategy recommended. This article summarizes ICHD-3 diagnostic criteria, differences from general migraine, and evidence-based treatment and self-management strategies.

Medical Background — Why Does Migraine Worsen Around Menstruation?

Approximately 50–60% of reproductive-age women with migraine report an association between migraine and menstrual cycle, and about 20% of these meet strict criteria for “Pure Menstrual Migraine (ICHD-3 A1.1.1)” (MacGregor, Lancet Neurol, 2015; Vetvik & MacGregor, Lancet Neurol, 2017). The core pathophysiology is estrogen withdrawal occurring in the late luteal phase. Since Somerville’s landmark study (Neurology, 1972), it has been consistently demonstrated that the abrupt decline in estrogen concentration, rather than absolute estrogen levels, is more closely associated with migraine triggering.

Estrogen acts multilaterally on serotonin (5-HT) neurotransmission, calcitonin gene-related peptide (CGRP) expression, magnesium metabolism, and pain control circuits (periaqueductal gray). Therefore, when estrogen levels drop suddenly, increased CGRP secretion, decreased serotonin neurotransmission, and lowered pain threshold occur simultaneously, resulting in stronger and more sustained attacks compared to general migraine. Additionally, elevated prostaglandin levels (PGE2, PGF2α) during menstruation amplify pain perception.

Diagnostic Criteria (ICHD-3) and Differential Diagnosis Points

The International Classification of Headache Disorders, 3rd edition (ICHD-3) appendix classifies menstrually-related migraine into two categories:

• Pure Menstrual Migraine Without Aura (A1.1.1): Migraine without aura attacks occur exclusively between 2 days before and 3 days after menstrual onset in at least 2 of 3 consecutive menstrual cycles, with no attacks at other cycle phases.
• Menstrually-Related Migraine Without Aura (A1.1.2): Attacks occur during the same timeframe, but additional attacks appear at other cycle phases.

In clinical practice, accurate diagnosis requires patients to maintain a headache diary for at least 3 or more cycles. Diagnosis is difficult based solely on vague complaints such as “I frequently have headaches around my period.”

Key Differential Points:

• Difference from tension-type headache: Menstrual migraine commonly presents with throbbing quality, unilateral location, and associated nausea, vomiting, photophobia, and phonophobia. Tension-type headache is characterized by bilateral pressure sensation without autonomic symptoms.
• Difference from Premenstrual Syndrome (PMS) and Premenstrual Dysphoric Disorder (PMDD): PMS/PMDD involve widespread emotional and physical symptoms with headache as a subsidiary symptom. Menstrual migraine has headache as the sole primary symptom and meets ICHD-3 diagnostic criteria for migraine.
• Secondary headache differentiation when warning signs present: Newly onset thunderclap headache, neurological deficits, fever, visual disturbances, or sudden pattern changes require immediate imaging studies.

Treatment and Self-Management — Acute Phase Plus “Mini-Prophylaxis” Strategy

Menstrual migraine follows general migraine treatment principles, with the following additional strategies recommended:

1) Acute Phase Treatment

• NSAIDs (naproxen 500–550 mg, ibuprofen 600–800 mg) — early administration immediately after attack onset.
• Triptans (sumatriptan 50–100 mg, zolmitriptan 2.5–5 mg, frovatriptan 2.5 mg) — administer within 1–2 hours. Given high recurrence rate in menstrual migraine, consider additional dosing after 12–24 hours or concurrent NSAID use.
• Combination therapy (triptan + naproxen) shows superior efficacy compared to monotherapy according to randomized controlled trial evidence (Brandes et al., JAMA, 2007).

2) Mini-Prophylaxis

A strategy of short-term preventive medication administration for 5–7 days beginning 2 days before menstrual onset in patients with relatively predictable attack cycles.

• Frovatriptan 2.5 mg twice daily — recommended at evidence level B by AAN/AHS guidelines (Silberstein et al., Neurology, 2012).
• Naproxen 550 mg twice daily.
• Magnesium oxide 400–600 mg once daily (starting from cycle day 15) — an effective supplementary option in patients with magnesium deficiency.
• Estrogen stabilization via oral contraceptives (continuous use or extended-cycle regimen) is effective in some patients but is contraindicated in patients with migraine with aura due to increased risk of ischemic stroke (Sacco et al., Cephalalgia, 2017).

3) Lifestyle Management

• Regular sleep (7–8 hours) beginning one week before menstruation, maintaining consistent caffeine intake (avoiding abrupt reduction), adequate hydration.
• Concurrent maintenance of menstrual diary and headache diary to confirm patterns and determine mini-prophylaxis timing.
• Stress management (progressive muscle relaxation, mindfulness meditation) shows increased effectiveness when combined with cognitive behavioral therapy.
• Identification and avoidance of individual dietary triggers including processed foods, MSG, aspartame, and tyramine-containing foods (aged cheese, red wine).

Warning Signs — When Immediate Medical Consultation Is Necessary

The following symptoms warrant consideration of secondary headache rather than simple menstrual migraine, requiring immediate emergency department or neurology evaluation:

• Sudden onset of severe headache (thunderclap headache).
• Fever with neck stiffness.
• Unilateral visual field loss, hemiparesis, speech disturbance, or other neurological deficits.
• Headache with first onset after age 50.
• Newly developed headache during pregnancy or postpartum period.
• Aura duration exceeding 1 hour or aura accompanied by motor weakness.

Particularly in women with migraine with aura, the risk of ischemic stroke increases 2–4-fold with smoking and high-dose estrogen-containing oral contraceptive use, making specialist consultation essential (Sacco et al., Cephalalgia, 2017; Bousser & Welch, Lancet Neurol, 2005).

Conclusion — Accurate Diagnosis as the Foundation for Treatment

Menstrual migraine is not simply “part of menstrual pain” but rather a distinct clinical phenotype clearly mediated by hormonal changes. Following headache diary documentation over 3 cycles, we recommend obtaining accurate diagnosis through neurology or headache clinic consultation, and establishing a personalized strategy combining acute treatment, mini-prophylaxis, and lifestyle management. Appropriate management alone can reduce the frequency and intensity of menstrual migraine attacks by more than 50%.

※ Medical Disclaimer: This article is provided for general informational purposes and does not replace individual patient diagnosis and treatment decisions. Medication use and preventive strategies must be determined in consultation with your physician.